Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 1997

View Archived Issues

Anticonvulsants with favorable protection indices reported by Canadian researchers

Teva presents potential antipsoriatic agents

AGE inhibitors reported by Alteon

Antineoplastic retinoid compounds disclosed

Merck Frosst discloses leukotriene antagonists

Dual PDE IV/TNF inhibitors from Pfizer

Neurotrophic rotamase inhibitors described by Guilford

American Home Products describes antiproliferative agents

Sulfonamide derivatives for inhibition of cell adhesion

Use of Home Access HIV test system encouraged

Positive phase II results reported for LiquiVent

Study suggests benefit of EchoGen for prostate cancer diagnosis

Menorest approved in 29 markets

Development partner sought for new wound dressing

IDEC receives patent coverage for platform technology

Maxim's lead product approaches pivotal trials

NexMed licenses alprostadil cream

Alexion receives grant for complement inhibitors

Roberts receives approvable letter from FDA for Agrylin

Meridian receives approval for ulcer test

Novartis launches once-daily hypertension Rx

Cephalon and Chiron seek FDA approval for rhIGF-1

Melatonin in immunity, aging and cancer

ICN and Roche extend licensing agreement

Arthritis gene therapy appears to hold promise

Servier describes 5-HT3 agonist with additionial antagonist-like properties

Potential cognition-enhancing agent described by Rotta

MGI Pharma seeks FDA approval of new indication for Salagen Tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...